CA2681639A1 - Compounds and methods for treatment of disorders associated with er stress - Google Patents

Compounds and methods for treatment of disorders associated with er stress Download PDF

Info

Publication number
CA2681639A1
CA2681639A1 CA002681639A CA2681639A CA2681639A1 CA 2681639 A1 CA2681639 A1 CA 2681639A1 CA 002681639 A CA002681639 A CA 002681639A CA 2681639 A CA2681639 A CA 2681639A CA 2681639 A1 CA2681639 A1 CA 2681639A1
Authority
CA
Canada
Prior art keywords
independently
lower alkyl
substituted
occurrence
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002681639A
Other languages
English (en)
French (fr)
Inventor
Teoman Uysal
Nicholas D.P. Cosford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SYNDEXA PHARMACEUTICALS CORP
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2681639A1 publication Critical patent/CA2681639A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002681639A 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with er stress Abandoned CA2681639A1 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US78533806P 2006-03-22 2006-03-22
US78533506P 2006-03-22 2006-03-22
US78515406P 2006-03-22 2006-03-22
US78518506P 2006-03-22 2006-03-22
US78532806P 2006-03-22 2006-03-22
US78523506P 2006-03-22 2006-03-22
US78518206P 2006-03-22 2006-03-22
US78503406P 2006-03-22 2006-03-22
US78500706P 2006-03-22 2006-03-22
US78503506P 2006-03-22 2006-03-22
US60/785,335 2006-03-22
US60/785,154 2006-03-22
US60/785,235 2006-03-22
US60/785,035 2006-03-22
US60/785,328 2006-03-22
US60/785,007 2006-03-22
US60/785,182 2006-03-22
US60/785,338 2006-03-22
US60/785,034 2006-03-22
US60/785,185 2006-03-22
PCT/US2007/007228 WO2007111994A2 (en) 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with er stress

Publications (1)

Publication Number Publication Date
CA2681639A1 true CA2681639A1 (en) 2007-10-04

Family

ID=38541676

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002681639A Abandoned CA2681639A1 (en) 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with er stress

Country Status (6)

Country Link
US (1) US20090131384A1 (OSRAM)
EP (1) EP2001897A2 (OSRAM)
JP (1) JP2009530399A (OSRAM)
AU (1) AU2007230991A1 (OSRAM)
CA (1) CA2681639A1 (OSRAM)
WO (1) WO2007111994A2 (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5101292B2 (ja) 2004-10-26 2012-12-19 ドルビー ラボラトリーズ ライセンシング コーポレイション オーディオ信号の感知音量及び／又は感知スペクトルバランスの計算と調整
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2009067493A2 (en) * 2007-11-19 2009-05-28 Envivo Pharmaceuticals, Inc. 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
MX2010005776A (es) 2007-11-27 2010-08-31 Ardea Biosciences Inc Nuevos compuestos y composiciones y metodos de uso.
JP2011507909A (ja) 2007-12-20 2011-03-10 エンビボ ファーマシューティカルズ インコーポレイテッド 四置換ベンゼン
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
AU2009320350B2 (en) * 2008-11-03 2015-09-24 Tufts University Methods and compositions for inhibiting Clostridium difficile spore germination and outgrowth
EP2255813A1 (en) * 2009-05-29 2010-12-01 The Royal College of Surgeons in Ireland Derivatives of ursodeoxycholic acid for the treatment of diarrhoea
PL2519100T3 (pl) 2009-12-29 2017-09-29 Mapi Pharma Limited Związki pośrednie i sposoby wytwarzania tapentadolu i pokrewnych związków
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
KR20190061096A (ko) 2010-04-22 2019-06-04 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
WO2011159840A2 (en) 2010-06-16 2011-12-22 Ardea Biosciences, Inc. Phenylthioacetate compounds, compositions and methods of use
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PL2776028T3 (pl) 2011-11-03 2019-03-29 Ardea Biosciences, Inc. 3,4-di-podstawiony związek pirydynowy, sposoby jego zastosowania i zawierające go kompozycje
AU2013256362A1 (en) * 2012-05-01 2014-11-13 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and FXR agonists: compositions and methods of use
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9968575B2 (en) 2012-09-27 2018-05-15 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
CN105431405B (zh) * 2013-03-14 2018-06-01 澳门大学 分离自益智仁的新抗神经变性天然化合物及其全合成
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
EP3215179A4 (en) * 2014-11-06 2018-07-25 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
JP2017535570A (ja) 2014-11-26 2017-11-30 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
MX2017010376A (es) 2015-02-11 2017-12-20 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
WO2016161003A1 (en) 2015-03-31 2016-10-06 Enanta Phamraceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
DE102017005884A1 (de) * 2016-07-07 2018-01-11 Merck Patent Gmbh Elektronisches Schaltelement
KR102499441B1 (ko) 2016-11-29 2023-02-13 이난타 파마슈티칼스, 인코포레이티드 술포닐우레아 담즙산 유도체의 제조 방법
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
DE102018004733A1 (de) 2018-06-14 2019-12-19 Merck Patent Gmbh Verfahren zur Herstellung eines elektronischen Bauteils enthaltend eine selbstorganisierte Monolage
CN116925168A (zh) 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
EP4378946A4 (en) * 2021-07-26 2025-07-30 Shaperon Inc NOVEL COMPOUND INHIBITING TNF-A GENERATION AND INFLAMMASOME ACTIVITY AND PREPARATION METHOD THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1152801B (it) * 1982-08-17 1987-01-14 Proter Spa Composti steroidei ad attivita' coleretica, processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo
JPS60161996A (ja) * 1984-02-01 1985-08-23 Eisai Co Ltd ケノデオキシコ−ル酸またはウルソデオキシコ−ル酸誘導体およびその製造法ならびにそれを含有する医薬
JP2616845B2 (ja) * 1991-02-21 1997-06-04 清水化学株式会社 システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
JPH0959162A (ja) * 1995-08-28 1997-03-04 Makoto Takahashi 胆石溶解剤
AU2001253226B2 (en) * 2000-04-07 2006-06-08 University Of Maryland, Baltimore Bile acid containing prodrugs with enhanced bioavailability
AU2002230398A1 (en) * 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs

Also Published As

Publication number Publication date
WO2007111994A2 (en) 2007-10-04
JP2009530399A (ja) 2009-08-27
WO2007111994A3 (en) 2008-06-12
AU2007230991A1 (en) 2007-10-04
US20090131384A1 (en) 2009-05-21
EP2001897A2 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
CA2681639A1 (en) Compounds and methods for treatment of disorders associated with er stress
JP6101675B2 (ja) 代謝病の治療用の化合物
CN101605754B (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的维生素a酸类和类维生素a酸化合物的前药
AU2007319848B2 (en) Compounds and methods for inhibiting the interaction of Bcl proteins with binding partners
TWI351395B (en) Large-scale synthesis of selective androgen recept
CN103096895B (zh) 烟酸模拟物及其使用的方法
TW200422041A (en) Method of treatment for sexual dysfunction
TW201336831A (zh) 作為鈣感測受體調節劑之取代二氫苯並哌喃化合物
US20250313522A1 (en) Phenoxy carboxylic acid compounds and medical uses thereof
CN103044250B (zh) 羧酸衍生物类化合物及其制备方法和应用
IL307865A (en) Sgc stimulators
CN102532114B (zh) 烟酸衍生物,其制备方法及其药物组合物
CN102659609A (zh) 非诺贝特酸盐及其制备方法和应用，以及其药物组合物
AU2013257710B2 (en) Compositions and methods for the treatment of neurological disorders
CN102659570B (zh) 二氟非诺贝特酸及其在药学上可接受的盐，以及它们的制备方法和应用
JP2024041865A (ja) パ－キンソン病治療用の新規高透過薬物及びその組成物
WO2015120610A1 (en) Gpr142 agonist compound
CN102432607A (zh) 一种吡嗪异喹啉衍生物在制备治疗血吸虫药物中的应用
US20130317034A1 (en) Combination therapy for treating diabetes
US20260001833A1 (en) Compounds, compositions, and methods for reducing production of trimethylamine
CN116472264A (zh) 一种药物偶联物、及其制备方法和用途
JP2009051731A (ja) 新規アスコクロリン誘導体化合物及びそれを含有する医薬組成物
WO2003041694A2 (en) Use of compounds comprising iodine, strontium and ascorbic acid as well as either bismuth, zinc or potassium in the treatment of aids
US20150126568A1 (en) Compositions and methods for the treatment of hypertension and management of diabetic kidney disease
TW202515549A (zh) 橋聯三環胺甲醯基吡啶酮化合物及其用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130322